Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.

@article{Urban2013TargetingTP,
  title={Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.},
  author={Daniel Urban and Janine Poess and Michael B{\"o}hm and Ulrich Laufs},
  journal={Journal of the American College of Cardiology},
  year={2013},
  volume={62 16},
  pages={1401-8}
}
Hypercholesterolemia is a major risk factor for cardiovascular diseases, increasing the incidence of myocardial infarction and death. Statin-induced lowering of low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular morbidity and mortality. However, many individuals treated with statins do not achieve their target levels of LDL-C, and thus, LDL-associated residual risk remains. Gain-of-function mutations of the proprotein convertase subtilisin/kexin type 9 (PCSK9) are associated… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 74 extracted citations

Alirocumab: A Review in Hypercholesterolemia.

American journal of cardiovascular drugs : drugs, devices, and other interventions • 2016
View 8 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 78 references

Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice

M Denis, J Marcinkiewicz, A Zaid
Circulation • 2012
View 5 Excerpts
Highly Influenced

of Health

U. S. National Institute
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER). Available at: http://clinicaltrials.gov/ct2/show/ NCT01764633. Accessed July 16, • 2013
View 1 Excerpt

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

The New England journal of medicine • 2012
View 1 Excerpt

Similar Papers

Loading similar papers…